IVIVC

Results: 18



#Item
1© World Health Organization WHO Technical Report Series, No. 937, 2006 Annex 7 Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish

© World Health Organization WHO Technical Report Series, No. 937, 2006 Annex 7 Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish

Add to Reading List

Source URL: apps.who.int

Language: English - Date: 2006-11-21 08:38:00
2FY 2013 Awarded GDUFA Regulatory Research Contracts and Grants FY2014 Extension or Expansion Development of In Vivo Predictive Dissolution Method for Orally Inhaled Drug Products • Multiple Awards to: University of Bat

FY 2013 Awarded GDUFA Regulatory Research Contracts and Grants FY2014 Extension or Expansion Development of In Vivo Predictive Dissolution Method for Orally Inhaled Drug Products • Multiple Awards to: University of Bat

Add to Reading List

Source URL: www.fda.gov

Language: English
3Use and Limitations of In Vitro Dissolution Testing: Topic Introduction and Overview

Use and Limitations of In Vitro Dissolution Testing: Topic Introduction and Overview

Add to Reading List

Source URL: www.fda.gov

Language: English
4Biopharmaceutics Risk of OrallyAdministered Products FY 2014 GDUFA Regulatory Science Initiatives Part 15 Public Meeting Silver Spring, MD  James E. Polli and Tricia Ting

Biopharmaceutics Risk of OrallyAdministered Products FY 2014 GDUFA Regulatory Science Initiatives Part 15 Public Meeting Silver Spring, MD James E. Polli and Tricia Ting

Add to Reading List

Source URL: www.fda.gov

Language: English
5Biorelevant In-Vitro Release Testing of NonOral Dosage Forms – FDA Perspectives Tapash Ghosh, Ph.D Team Leader, Biopharmaceutics, ONDQA, FDA Annual AAPS, San Antonio, Texas November 11, 2013 Disclaimer: The contents of

Biorelevant In-Vitro Release Testing of NonOral Dosage Forms – FDA Perspectives Tapash Ghosh, Ph.D Team Leader, Biopharmaceutics, ONDQA, FDA Annual AAPS, San Antonio, Texas November 11, 2013 Disclaimer: The contents of

Add to Reading List

Source URL: www.fda.gov

Language: English
6What are clinically relevant dissolution specifications?

What are clinically relevant dissolution specifications?

Add to Reading List

Source URL: www.fda.gov

Language: English
7What are clinically relevant dissolution specifications?

What are clinically relevant dissolution specifications?

Add to Reading List

Source URL: www.fda.gov

Language: English
8Generic Drug User Fee Amendments of 2012 Regulatory Science Initiatives: 4. QbD and 6. Anti-epileptic drugs 7. BCS  James E. Polli

Generic Drug User Fee Amendments of 2012 Regulatory Science Initiatives: 4. QbD and 6. Anti-epileptic drugs 7. BCS James E. Polli

Add to Reading List

Source URL: www.fda.gov

Language: English
9In Vitro & CFD Bioequivalence Testing for Orally Inhaled Drug Products Peter R Byron, Michael Hindle and Worth Longest Schools of Pharmacy and Engineering, Virginia Commonwealth University, Richmond, VA Research support:

In Vitro & CFD Bioequivalence Testing for Orally Inhaled Drug Products Peter R Byron, Michael Hindle and Worth Longest Schools of Pharmacy and Engineering, Virginia Commonwealth University, Richmond, VA Research support:

Add to Reading List

Source URL: www.fda.gov

Language: English
10Package ‘ivivc’ September 23, 2014 Version[removed]Date[removed]Title A data analysis tool for in vitro-in vivo correlation (IVIVC) Author Hsin-ya Lee, Yung-jin Lee

Package ‘ivivc’ September 23, 2014 Version[removed]Date[removed]Title A data analysis tool for in vitro-in vivo correlation (IVIVC) Author Hsin-ya Lee, Yung-jin Lee

Add to Reading List

Source URL: cran.r-project.org

Language: English - Date: 2014-09-23 01:30:22